ArticleActa oncologica (Stockholm, Sweden)2024
Epidemiology of mastocytosis: a population-based study (Sweden).
Article in Acta oncologica (Stockholm, Sweden), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 20 citations in OpenAlex.
- Article
- Selective elimination of mast cells via Siglec-6-targeted nanodelivery of drug payload.The Journal of allergy and clinical immunology · 2026Article
- Extended multisystem manifestations of hereditary α-tryptasemia in an allergy center cohort.The journal of allergy and clinical immunology. Global · 2026Article
- Assessing real-world natural history of indolent systemic mastocytosis: A retrospective matched cohort study.The journal of allergy and clinical immunology. Global · 2026Article
- Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.Blood advances · 2026Article
- The Characteristics of 924 Cutaneous Mast Cell Tumours in Dogs ≤ 3 Years of Age-With a Short Literature Review of Feline, Equine, and Human Proliferative Mast Cell Disorders.Veterinary sciences · 2026Article
- Sexual Dimorphism in Allergic and Mast Cell-Associated Diseases.Clinical reviews in allergy & immunology · 2026Review
- Management of skeletal-related events and fracture prevention in systemic mastocytosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Review
- Comparative Analysis of Pediatric and Adult Mastocytosis: Clinical Presentation, Triggers, and Treatment Patterns from a Tertiary Care Registry.Children (Basel, Switzerland) · 2026Article
- Diagnosis, management and the burden of symptoms of mastocytosis from the physician's perspective: A nationwide study.British journal of haematology · 2025Article
- Gender and Allergy: Mechanisms, Clinical Phenotypes, and Therapeutic Response-A Position Paper from the Società Italiana di Allergologia, Asma ed Immunologia Clinica (SIAAIC).International journal of molecular sciences · 2025Review
- Article
- Evaluating Melanoma Risk in Adult Mastocytosis: Potential Impact of Detection Bias - A Registry-based Study (Sweden).Acta dermato-venereologica · 2025Article
- Clinical and Biological Characteristics of Four Patients with Aggressive Systemic Mastocytosis Treated with Midostaurin.Biomedicines · 2025Article
- Real-world characteristics of systemic mastocytosis in Romania: insights from a reference-center-based descriptive study.Journal of medicine and life · 2025Observational
- Article
- Mastocytosis.Nature reviews. Disease primers · 2025Review
- Role of sclerostin in mastocytosis bone disease.Scientific reports · 2025Article
- Chronic Anaphylaxis With Indolent Systemic Mastocytosis: A Case Report.Case reports in hematology · 2025Article
- Prevalence and incidence of mastocytosis in adults: a Danish nationwide register study.European journal of epidemiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMastocytosis is a disease characterized by accumulation of aberrant mast cells and mediator-related symptoms and is divided into systemic mastocytosis (SM) and cutaneous mastocytosis (CM). The epidemiology of mastocytosis remains incompletely understood.
objectiveTo estimate the incidence, prevalence, overall survival (OS) and burden of comorbidities in adult mastocytosis patients identified in Swedish population-based registries.
methodsIndividuals (≥ 20 years of age) with a mastocytosis diagnosis in the National Patient Register (NPR) and/or the Swedish Cancer Register (SCR) between 2001 and 2018, were identified. In a matched cohort design, for each case five randomly selected mastocytosis-free comparators matched on age, sex, and county of residence were chosen from the Population Register. The Kaplan-Meier method was used to compare OS between individuals with mastocytosis and comparators. Information on concomitant disease at baseline was assessed by use of the Charlson Comorbidity Index (CCI).
resultsWe identified 2,040 adults with a mastocytosis diagnosis yielding an annual incidence of 1.56 per 100,000 (95% CI 1.29-1.87) and a prevalence of 23.9 per 100,000 (95% CI 22.8-25.0). The comorbidity burden was higher, and the OS lower, in patients with mastocytosis compared to comparators.
interpretationWe found a higher incidence and prevalence of mastocytosis compared to assessments in other settings and confirmed that the prognosis generally is favorable. Of special note was evidence of a higher comorbidity burden in mastocytosis patients compared to the background population. LIMITATIONS: Underreporting and inconsistencies in the use of diagnostic codes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.